Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Western Alliance Bancorporation (WAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Western Alliance Bancorporation — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221.74 (market cap $29.60B), while Western Alliance Bancorporation trades at $82.24 (market cap $8.89B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 3.3× Western Alliance Bancorporation's market cap, and Western Alliance Bancorporation pays a 2.06% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | WAL | |
|---|---|---|
Market Cap | $29.60B | $8.89B |
Sector | Health | Financials |
52-Week High | $491.22 | $96.08 |
52-Week Low | $205.48 | $66.70 |
Enterprise Value | $27.56B | — |
Dividend Yield | — | 2.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $216.98, down 1.01% with bearish technical signals. The company shows strong revenue growth from $1.0B in 2022 to $3.7B in 2025, turning profitable with $314M net income. However, recent Q2 2026 earnings missed expectations, and multiple law firms are investigating potential securities fraud. Analyst consensus remains bullish with a $370.07 price target despite recent volatility.
The stock faces near-term pressure from legal investigations and earnings volatility, but strong fundamentals and analyst support suggest long-term potential. Key risks include legal outcomes and execution on growth targets, while the 71% upside to consensus target offers opportunity if the company can maintain its revenue trajectory.
Western Alliance Bancorporation (WAL) trades at $81.64, up 1.44% today, with a neutral technical signal and bullish analyst consensus. The stock shows strong fundamentals, including a P/E of 9.2 and net income margin of 25.43%, supported by recent earnings beats. Recent developments include the launch of WA VenueX, an institutional financial platform, and recognition as Arizona's top bank by Forbes in 2026.
The outlook for WAL is positive, with a consensus price target of $93.86 implying 15% upside, driven by revenue growth and profitability. Risks include negative operating cash flow and high interest expenses. Institutional sentiment is mixed, with some firms reducing stakes, but overall analyst ratings remain heavily bullish.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Western Alliance Bancorporation
Western Alliance Bancorporation is a top-performing bank holding company that operates a dual business model: high-touch regional banking and specialized national business lines. It serves niche industries—including technology, life sciences, and homeowners associations—providing sophisticated commercial lending and treasury solutions that bridge the gap between regional service and national scale.
Read more on WAL →
